Loading
Chronic Myeloid Leukemia Treatments / Acute Myeloid Leukemia Research / Acute Lymphoblastic Leukemia Research · Journal article
International Journal of Clinical Pharmacy · September 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This bibliometric analysis maps global research output and emerging trends in therapeutic drug monitoring for leukemia from 2001 to 2025, identifying 859 publications with growing activity, particularly in tyrosine kinase inhibitors and precision dosing strategies. The analysis is descriptive and identifies research hotspots rather than generating new clinical evidence, serving as a landscape review for the field.
Bibliometric analysis with systematic literature search and visualization. Published articles on therapeutic drug monitoring in leukemia indexed in Web of Science Core Collection.. n = 859. Global analysis; United States and China identified as leading contributors..
859 papers retrieved over 2001–2025 period, with highest output of 58 papers between 2024–2025 United States and China were leading contributors to publication volume University of Texas MD Anderson Cancer Center ranked first among contributing institutions
Current research hotspots include tyrosine kinase inhibitors, Bcr-Abl inhibitors, asparaginase, drug interactions, and safety management
This analysis informs researchers and clinicians about the evidence base and research priorities in TDM for leukemia, highlighting growing interest in precision dosing and drug interactions. It provides context for emerging therapeutic agents and may guide clinical pharmacy practice development, but does not itself establish clinical efficacy.
A bibliometric analysis of publication trends and research hotspots in therapeutic drug monitoring for leukemia; describes the research landscape rather than testing a clinical hypothesis or reporting primary outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This analysis informs researchers and clinicians about the evidence base and research priorities in TDM for leukemia, highlighting growing interest in precision dosing and drug interactions. It provides context for emerging therapeutic agents and may guide clinical pharmacy practice development, but does not itself establish clinical efficacy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Leukemia treatment has evolved rapidly over the past decade, with the introduction of targeted therapies, immunotherapies, and increasingly complex pharmacotherapeutic regimens. Many antileukemic agents and supportive medications exhibit substantial pharmacokinetic variability and have narrow therapeutic windows. Therefore, therapeutic drug monitoring (TDM) has emerged as an important strategy for optimizing individualized pharmacotherapy, improving treatment efficacy, and reducing drug-related toxicity. However, the overall research landscape, development trajectory, and emerging trends of TDM in leukemia have not been systematically evaluated. This study aimed to systematically analyze global research trends and hotspots in TDM for leukemia between 2001 and 2025 using bibliometric methods and to provide insights into future research directions and clinical pharmacotherapy applications. Publications related to TDM in leukemia published between January 1, 2001, and December 31, 2025, were retrieved from the Web of Science Core Collection database. A topic-based search strategy was used to identify the relevant articles. Bibliometric analysis and visualization were conducted using VOSviewer and CiteSpace to evaluate publication output, collaboration networks among countries, institutions, and authors, journal distribution, highly cited publications, citation bursts, and keyword co-occurrence. A total of 859 papers were retrieved, with the highest output (58 papers) observed between 2024 and 2025. The United States and China contributed the most publications. The University of Texas MD Anderson Cancer Center ranked first among the institutions. Highly cited papers primarily focused on pharmacotherapy for hematologic malignancies, pharmacodynamics and pharmacokinetic studies, and pre-transplant medication regimens. Burst analysis indicates that TDM in leukemia treatment has progressively evolved from early preliminary studies on exposure–response relationships to the implementation of precision dosing strategies and clinical guidelines, continuously expanding to cover an increasing number of therapeutic agents in leukemia treatment. Current research hotspots include tyrosine kinase inhibitors (particularly Bcr-Abl inhibitors), asparaginase, drug interactions, and safety management issues. From 2001 to 2025, research activities on TDM in leukemia treatment have shown continuous growth, with substantial expansion in both scope and depth. TDM is gradually becoming an increasingly important component of leukemia pharmacotherapy and may play a key role in supporting precision medicine and optimizing treatment outcomes in leukemia patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.